Introduction {#Sec1}
============

The introduction of imatinib to therapy of advanced gastrointestinal stromal tumors (GIST) has dramatically improved the outcomes of these tumors \[[@CR1], [@CR2]\]. Imatinib as tyrosine kinase inhibitor inhibiting KIT/PDGFRA (platelet-derived growth factor receptor alpha) and their downstream signaling cascade in GIST cells is currently standard of care in the first-line therapy of inoperable and/or metastatic tumors \[[@CR3]\], and became the model of targeted therapy of solid tumors. Its efficacy has been also proven recently in adjuvant setting after resection of primary high-risk tumors \[[@CR4], [@CR5]\]. However, a majority of patients eventually develop clinical resistance to imatinib. Over the last few years, major progress has been made in elucidating the mechanism of disease progression and resistance to imatinib such as secondary mutations in KIT and/or PDGFRA kinase domains. Currently, the sole-approved second-line drug is sunitinib---a multi-targeted agent \[[@CR6]\]. Moreover, a number of new generation tyrosine kinase inhibitors (as regorafenib, registered recently in USA), alone or in combination, are being evaluated at present alongside treatment options alternative to inhibiting the KIT signaling pathway \[[@CR7]\].

There are limited data regarding the long-term outcomes of metastatic GIST outside the clinical trials in routine practice. The aim of this large contemporary series of inoperable/metastatic GIST was to identify factors related to progression-free and overall survival (OS) of patients starting imatinib therapy as well as to attempt to identify the factors related to subgroup of patients with the long-term survival.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

In this observational study, we analyzed collected prospectively data of 430 consecutive patients treated initially with imatinib mesylate (according to approved registration) due to inoperable and/or metastatic histologically confirmed, CD117-positive GIST, who were treated or referred to tertiary sarcoma center within framework of the Polish Clinical GIST Registry between September 1, 2001 and December 31, 2010. Each patient provided informed consent for the study. The study has been approved by the local Bio-Ethics Committee according to Good Clinical Practice Guidelines. Patients did not undergo any further selection. The distribution of clinical and pathological data of patients included in the study is listed in Table [1](#Tab1){ref-type="table"}. There were 226 male and 204 female patients, with median age at the start of imatinib therapy 58 years (range 15--89).Table 1Characteristics of 430 patients treated initially with imatinib due to advanced GISTClinicopathological featuresNo. of patientsTotal number of patients430 (100 %)Age (years) at the start of imatinib therapy Median (range) mean58 (15--89) 57 ≤4042 (9.8 %) \>40388 (90.2 %)Gender Female204 (47.4 %) Male226 (52.6 %)The period of initiation of imatinib therapy (years) 2001--2003100 (23.3 %) 2004--2006166 (38.6 %) 2007--2010164 (38.1 %)Primary tumor site Stomach151 (35.1 %) Duodenum23 (5.4 %) Small bowel179 (41.6 %) Large bowel/rectum34 (7.9 %) Other or intraperitoneally with unknown primary origin43 (10.0 %)The maximal diameter of the largest tumor (mm) Median (range)73 (10--400) ≤50108 (25.1 %) \>50--100105 (24.4 %) \>100118 (27.4 %) Data not available99 (23.0 %)Resection of residual disease during imatinib therapy Yes94 (21.9 %) No336 (78.9 %)Presence of liver metastases at imatinib start Yes220 (51 %) No210 (49 %)Tumor genotype^a^ *KIT* exon 11139 (63.2 %) *KIT* exon 929 (13.1 %) Wild type34 (15.5 %) *PDGFRA* exon 18 D842V9 (4.1 %) Other9 (4.1 %)Baseline albumin level Low (\<35 g/l)58 (13.5 %) Normal (\>35 g/l)230 (53.5 %) Data not available142 (33.0 %)Baseline hemoglobin level Low (\<11 g/100 ml)65 (15.1 %) Normal (≥11 g/100 ml)278 (64.7 %) Data not available87 (20.2 %)Baseline neutrophils count High (\>5 × 10^9^/l)72 (16.7 %) Normal (\<5 × 10^9^/l)262 (60.9 %) Data not available96 (22.3 %)Performance status (WHO score) Poor ≥275 (17.5 %) Good \<2272 (63.2 %) Data not available83 (19.3 %)^a^Mutational status was evaluated in 220 cases

All but eight patients (who started imatinib therapy from 800 mg/day) were treated with imatinib in initial dose of 400 mg daily. All patients were followed carefully with median follow-up time for survivors of 51 months. The objective response of GIST to imatinib therapy was evaluated with serial CT examinations (performed every 2--3 months), according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 \[[@CR8]\]. In doubtful cases of progressive disease, additional Choi's criteria were applied \[[@CR9]\]. In the case of progression or unacceptable toxicity (three cases), patients were treated with imatinib at the higher doses (600--800 mg daily) or the therapy was immediately changed to sunitinib. One hundred and eighty-eight progressing patients were thereafter treated with sunitinib (since 2005). Subsequently, patients were treated according to decision of treating physician with either best supportive care, experimental therapy (nilotinib or regorafenib), off-label use of sorafenib, reintroduction of imatinib, or chemotherapy.

Multidisciplinary team evaluated possibility of surgical treatment of residual lesions (liver and/or intraperitoneal metastases), which had been estimated as resectable after maximal response to imatinib (as described previously) \[[@CR10]\].

Genomic screening was performed for the presence of the *KIT* (exons 9, 11, 13, and 17) or *PDGFRA* (exons 12, 14, and 18) genes mutation in randomly selected 220 cases, based on DNA isolated from paraffin-embedded or fresh-frozen imatinib-naive tumor tissues, as previously described \[[@CR11]\].

Statistical analyses {#Sec4}
--------------------

All statistical analyses were performed using R 2.10.1 statistical program.[1](#Fn1){ref-type="fn"} For the survival analysis, the Kaplan--Meier estimator was used with the log-rank tests for bivariate comparisons. The primary objective of the study was to assess the OS of advanced GIST treated initially with imatinib as well as to identify the factors related to longer OS time. The secondary objectives were to estimate progression-free survival (PFS) on imatinib therapy and to describe the factors related to improved PFS time. OS time was calculated from the date of the start of imatinib treatment to the date of the most recent follow-up or death. PFS time was calculated from the date of the start of imatinib treatment to the date of the most recent follow-up, or progression or death due to the disease. The survival was assessed with respect to the following variables: demographic data (age at the start of imatinib therapy ≤40 or \>40 years; gender), the period of initiation of imatinib therapy (2001--2003 vs. 2004--206 vs. 2007--2010), primary tumor genotype (*KIT* exon 11, *KIT* exon 9, *PDGFRA* exon 18 D842V mutations, wild type, and other cases), the maximal diameter of the largest tumor at imatinib start, the presence versus absence of liver metastases, primary tumor site (gastric vs. duodenum vs. small bowel---ileum or jejunum vs. large bowel vs. other or intraperitoneally with unknown primary origin), baseline (1--7 days before start of imatinib therapy) albumin level (low \<35 g/l vs. normal \>35 g/l), baseline (1--7 days before start of imatinib therapy) hemoglobin level (low \<11 g/100 ml or normal ≥11 g/100 ml), baseline (1--7 days before start of imatinib therapy) neutrophils count (high \>5 × 10^9^/l vs. normal \<5 × 10^9^/l), baseline (1--7 days before start of imatinib therapy) performance status according to World Health Organization (WHO) (good: 0--1 vs. poor ≥2), and the fact of resection of GIST residual disease during imatinib therapy. In multivariate analysis of the factors associated with PFS, we used Cox proportional hazards models, applying the stepwise model building procedure that included all covariates significant at 20 % level in bivariate analysis. The best model was based on Akaike's criterion. The differences were considered statistically significant if the *p* values were \<0.05.

Results {#Sec5}
=======

Clinicopathological and mutational data {#Sec6}
---------------------------------------

During analyzed time periods, we have found decrease in median largest tumor size at the start of imatinib therapy: 90.5 mm (2001--2003) versus 74 mm (2004--2006) versus 58 mm (2007--2010) (*p* = 0.002).

The distribution of patients according to the tumor mutational status is shown in Table [1](#Tab1){ref-type="table"}. In total, 85 % of cases revealed a *KIT* or *PDGFRA* mutation (63 %---exon 11 *KIT*, 13 %---exon 9 *KIT*, 4.1 %---exon 18 *PDGFRA* D842V, and 4.1 %---other types of mutation).

Progression-free survival on imatinib therapy {#Sec7}
---------------------------------------------

Progression of disease during imatinib therapy was observed in 246 cases (57 %). Median PFS was 37.5 months, and estimated 5- and 8-year PFS rates were 37.0 and 27 %, respectively.

We have not observed significant differences in PFS between three analyzed periods of time (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Progression-free survival according to periods of time of initiation of imatinib therapy

In univariate analysis, the following factors correlated with shorter PFS (Table [2](#Tab2){ref-type="table"}a): lack of resection of residual disease during imatinib therapy, primary tumor located in duodenum or intraperitoneally with unknown primary origin, the maximal tumor diameter of the largest tumor \>100 mm, tumor mutation other than *KIT* exon 11, the younger age, low baseline albumin level, high baseline neutrophils count, low baseline hemoglobin level, and poor performance status.Table 2Univariate analysis for PFS (a) and OS (b) in the entire cohort of patientsFactorSubgroupPFS (months)5-year PFS95 % CI8-year PFS95 % CI*p* valueMedian95 % CI(a)GenderFemale43.633.0--49.437.730.7--46.430.623.6--39.70.508Male34.828.4--45.236.229.6--44.224.117.7--32.6Age≤4023.715.4--66.832.920.4--53.120.39.6--42.80.246\>4038.832.3--47.337.432.1--43.428.022.8--34.4The period of initiation of imatinib therapy (years)2001--200345.336.4--66.742.333.3--53.732.524.1--44.00.2732004--200639.630.8--50.235.828.5--44.824.517.9--33.62007--201030.026.3--42.338.130.0--48.538.130.0--48.5Resection of residual disease during imatinib therapyYesNA64.9--NA62.252.1--74.450.439.4--64.6\<0.001No27.524.2--34.129.023.8--35.419.714.8--26.3Primary tumor siteStomach35.57.4--38.542.133.9--52.331.823.5--43.0Duodenum21.28.13--NA12.62.3--69.112.62.3--69.10.0002Small bowel40.933.6--48.135.828.7--44.725.418.4--35.0Large bowel/rectum66.645.2--NA59.142.4--82.347.330.0--74.4Other or intraperitoneally with unknown primary origin15.97.4--38.515.86.6--38.111.94.2--33.8Presence of liver metastases at imatinib startYes40.733.2--50.937.130.5--45.123.817.6--32.20.858No33.027.8--45.436.729.8--45.331.324.3--40.3The maximal diameter of the largest tumor (mm)≤5056.544.9--86.449.138.4--62.631.921.2--48.00.003\>50--10066.643.6--NA53.243.0--65.839.028.5--53.6\>10027.321.8--40.927.819.8--39.221.814.3--33.1Tumor genotypeWild type20.611.5--NA34.019.2--60.227.213.2--55.90.005Exon 11 *KIT*47.336.4--66.641.933.5--52.531.623.1--43.2Exon 9 *KIT*20.914.0--38.818.67.9--43.718.67.9--43.7Exon 18 *PDGFRA* D842V2.31.7--NA22.26.5--75.422.26.5--75.4OtherNA5.2--NA57.130.1--100.057.130.1--100.0Baseline albumin levelNormal59.944.2--80.449.342.7--57.036.429.5--44.9\<0.001Low23.719.2--34.815.47.8--30.112.86.0--27.5Baseline neutrophils countNormal56.545.3--80.449.242.4--57.136.829.8--45.5\<0.001High20.216.9--28.720.912.5--34.715.68.2--29.9Baseline hemoglobin levelNormal56.544.9--75.748.742.0--56.436.029.1--44.4\<0.001Low19.415.9--26.618.09.9--32.715.07.4--30.1Performance status (WHO score)Good \<259.947.3--75.749.443.0--56.937.030.4--45.2\<0.001Poor ≥216.311.5--20.49.23.9--21.66.92.5--19.2All37.531.7--45.237.032.1--42.727.222.3--33.2--(b)GenderFemale78.360.6--NA57.250.0--65.547.339.5--56.70.706Male64.351.5--95.752.945.9--60.939.832.0--49.4Age≤40NA55.2--NA63.449.2--81.857.642.0--79.00.152\>4066.158.8--93.854.048.5--60.041.635.6--48.6The period of initiation of imatinib therapy (years)2001--200362.946.8--10752.142.9--63.342.933.9--54.40.5892004--200664.951.5--NA53.445.9--62.142.534.7--52.12007--201070.058.1--NA59.649.7--71.643.228.2--66.0Resection of residual disease during imatinib therapyYesNANA--NA80.371.8--89.967.456.6--80.3\<0.001No55.243.9--7046.841.0--53.435.629.3--43.2Primary tumor siteStomach93.445.1--NA53.645.3--63.445.836.2--57.8Duodenum61.855.2--NA57.135.9--91.130.510.9--84.90.002Small bowel70.860.6--102.458.250.6--67.041.032.7--51.4Large bowel/rectumNA46.6--NA64.949.1--85.664.949.1--85.6Other or intraperitoneally with unknown primary origin21.919.0--62.929.116.4--51.725.513.6--47.9Presence of liver metastases at imatinib startYes90.160.6--NA57.050.1--64.944.937.1--54.40.249No64.950.2--98.552.745.3--61.242.034.4--51.4The maximal diameter of the largest tumor (mm)≤50NA98.5--NA78.369.1--88.763.551.2--78.8\<0.001\>50--100124.796.7--NA65.355.5--76.761.050.6--73.6\>10046.837.9--63.739.630.4--51.627.218.2--40.6Tumor genotypeWild type66.114.23--NA52.937.4--74.747.031.0--71.20.157Exon 11 *KIT*82.460.60--NA59.651.0--69.747.037.5--58.9Exon 9 *KIT*78.355.20--NA60.243.5--83.542.625.5--71.1Exon 18 *PDGFRA* D842V15.58.33--NA33.313.2--84.033.313.2--84.0OtherNA17.20--NA66.737.9--100.066.737.9--100.0Baseline albumin levelNormal124.796.7--NA68.762.5--75.558.150.7--66.6\<0.001Low37.831.3--50.225.415.6--41.315.27.6--30.8Baseline neutrophils countNormal124.795.7--NA67.661.2--74.756.749.1--65.4\<0.001High37.829.4--49.331.921.8--46.622.813.8--37.7Baseline hemoglobin levelNormal106.493.4--NA65.859.5--72.754.146.8--62.6\<0.001Low38.831.7--52.829.919.2--46.624.514.5--41.3Performance status (WHO score)Good \<2124.796.7--NA70.064.2--76.558.451.3--66.5\<0.001Poor ≥227.521.9--43.412.76.2--26.38.53.4--21.3All70.859.9--95.754.949.8--60.643.437.7--50.0--*CI* confidence interval, *NA* not applicable

In the multivariate analysis (final Cox model), we identified the following independent predictive factors, which correlated with poorer PFS (Table [3](#Tab3){ref-type="table"}a): worse baseline WHO performance status, high baseline neutrocyte count, low baseline hemoglobin level, younger age, the lack of resection of residual disease, primary tumor site, and tumor mutation other than *KIT* exon 11.Table 3Multivariate analysis of prognostic factors for PFS (a) and OS (b)FactorSubgroupHR95 % CI*p* value(a)Age\>401.00≤401.8021.1875--2.73470.005Resection of residual disease during imatinib therapyYes1.00No0.35390.2420--0.5175\<0.001Primary tumor siteDuodenum1.00Small bowel0.72080.4097--1.26820.256Large bowel/rectum0.39590.1793--0.87410.022Stomach0.47110.2576--0.86130.014Other or intraperitoneally with unknown primary origin1.3150.6809--2.54010.415Tumor genotypeWild type1.00Exon 11 *KIT*0.58970.3458--1.00550.052Exon 9 *KIT*1.20.6183--2.32920.589Exon 18 *PDGFRA* D842V4.1021.6520--10.18510.002Other0.97460.2781--3.41540.968Baseline neutrophils countNormal1.00High1.721.1724--2.52480.006Baseline hemoglobin levelNormal1.00Low1.5921.0396--2.43850.032Performance status (WHO score)Good \<21.00Poor ≥22.791.8647--4.1755\<0.001(b)Resection of residual disease during imatinib therapyYes1.00No0.31790.20001--0.5052\<0.001Primary tumor siteDuodenum1.00Small bowel1.20.59257--2.43170.612Large bowel/rectum0.92140.36381--2.33370.863Stomach0.86930.41325--1.82850.712Other or intraperitoneally with unknown primary origin2.4371.08447--5.47450.031Presence of liver metastases at imatinib startYes1.00No1.3871.01151--1.90290.042The maximal diameter of the largest tumor (mm)≤501.00\>50--1001.040.60162--1.79800.888\>1001.6360.97002--2.75830.065Tumor genotypeWild type1.00Exon 11 *KIT*0.44660.24163--0.82540.01Exon 9 *KIT*0.61560.28451--1.33180.218Exon 18 *PDGFRA* D842V3.0491.142--8.14140.026Other0.40760.09017--1.84290.244Baseline albumin levelNormal1.00Low2.4151.48174--3.93630.0004Baseline hemoglobin levelNormal1.00Low1.0070.60318--1.68010.979Performance status (WHO score)Good \<21.00Poor ≥22.4271.53092--3.84910.0002*HR* hazard ratio, *CI* confidence interval

Overall survival {#Sec8}
----------------

At the time of analysis, 241 (56 %) patients were alive. Median OS was 37.5 months, and estimated 5- and 8-year PFS rates were 57 and 47 %, respectively (Fig. [2](#Fig2){ref-type="fig"}a).Fig. 2Overall survival: in the entire group of patients (**a**); according to maximal diameter of tumor at start of imatinib therapy in mm (**b**); according to the lack of resection of residual disease during imatinib therapy (**c**); and according to initial mutational status (**d**)

We have not observed significant differences in OS between three analyzed periods of time (data not shown).

The following factors significantly influenced OS in bivariate analysis (Table [2](#Tab2){ref-type="table"}b): poor baseline WHO performance status ≥2, baseline high neutrocyte count, baseline low albumin level, low baseline hemoglobin level, the maximal diameter of the largest tumor \>10 cm (Fig. [2](#Fig2){ref-type="fig"}b), and the lack of resection of residual disease during imatinib therapy (Fig. [2](#Fig2){ref-type="fig"}c). Patients with primary tumors carrying mutation D842V in exon 18 *PDGFRA* had substantially shorter OS reaching median OS only 15.5 months (Fig. [2](#Fig2){ref-type="fig"}d).

The following factors were found to be independent predictors of better OS according to multivariate analysis (Table [3](#Tab3){ref-type="table"}b): good baseline WHO performance status, normal baseline albumin level, the resection of residual disease during imatinib therapy, the presence of exon 11 *KIT* mutations, and (with borderline significance) the maximal tumor diameter of the largest tumor \>10 cm.

Discussion {#Sec9}
==========

Our data comprise the largest series of advanced GIST patients treated in routine practice and were collected prospectively in tumor-type-specific national registry with the long follow-up. Several conducted clinical trials confirmed high efficacy of imatinib in the treatment of inoperable/metastatic GIST \[[@CR1], [@CR2], [@CR12], [@CR13]\] as compared to historical clinical data with median survival of patients being 10--19 months \[[@CR3], [@CR14]\], with the current survival being strikingly superior \[[@CR15]\]. The median OS reported until now in few studies reached only from 4.0 to 6.4 years \[[@CR12], [@CR13], [@CR16]--[@CR21]\]. Our data confirm this superior survival. Moreover, although the spectacular response to imatinib therapy is time-limited and followed by the development of secondary resistance (after initial stabilization or response) in the majority of patients, still 1/4 of patients have not been progressing at 8 years of therapy with imatinib. The current PFS in our series on first-line therapy with imatinib is approximately 3 years, what is almost the same as in the recent Taiwanese one-institution study \[[@CR20]\], and it did not improve significantly over decade from the turning point of introduction of imatinib to clinical practice. However, we have found systematically decrease in maximal tumor burden during this period of time, what is probably related to better follow-up of patients after resection of primary tumor and earlier detection of recurrent disease. The cut-off value for tumor bulk which had significantly inferior impact on PFS and OS was 10 cm in our series defined as the single largest size of measurable lesions. It confirms the previous data that largest tumor may be related to higher likelihood of development of resistant clones and secondary mutations \[[@CR13], [@CR20], [@CR22]--[@CR25]\], and it underlines the utility of tumor bulk assessment by the single largest lesion.

We have previously identified some predictive factors for the benefit of imatinib therapy in terms of inhibition of disease progression in advanced GIST \[[@CR26]\]. Also, van Glabbeke and co-authors \[[@CR27]\] had reported data on distinctive predictive clinicopathological factors for initial and late resistance to imatinib in advanced GISTs, but this analysis did not include the genotyping of the tumor as well as the strategy of removal of residual disease during therapy with tyrosine kinase inhibitors. Currently, we have expanded the variables predictive for the long-term outcomes and survival of inoperable and/or metastatic GISTs treated initially with imatinib. Based on these results of univariate and multivariate analyses, we can identify the patients' factors which are related to benefits of longer survival: initial better performance status and laboratory test results (especially normal albumin level), primary tumor genotype (exon 11 *KIT* mutants and genotype other than exon 18 *PDGFRA* D842V), the smaller maximal size of the largest tumor, and resection of residual disease during imatinib therapy. These factors may account for the basis for development of the nomogram for PFS and OS \[[@CR28]\]. Laboratory factors as high granulocyte count, low hemoglobin level, or low albumin level together with poor general performance status were previously implied as predictive factors for resistance to imatinib therapy \[[@CR12], [@CR13], [@CR17], [@CR18], [@CR23], [@CR26], [@CR27]\]. Consistently with the results of present series, these factors can be related to generally more advanced and aggressive tumors, with higher inflammatory component influencing pharmacokinetics of the drug \[[@CR13], [@CR17], [@CR27], [@CR29], [@CR30]\].

In patients with available data on tumor genotype, we found consistently with results already reported \[[@CR12], [@CR31]--[@CR34]\] that the mutational status had significant impact on prognosis, with the best results for *KIT* exon 11 mutants in terms of PFS and OS. For OS, the effect of presence of *KIT* exon 11 as compared to *KIT* exon 9 mutations was less evident, which may be related to the impact of subsequent lines of therapy (mainly with sunitinib, which is more active for *KIT* exon 9 mutants \[[@CR35]\]. Notably, according to Blanke et al. \[[@CR13]\], the effect of exon 11 *KIT* mutations on OS mainly resulted from their strong effect during the first 30 months of treatment. We could not analyze the influence of higher dose of imatinib on PFS in subgroup of patients with *KIT* exon 9 mutations because all but eight patients started therapy from registered dose of 400 mg. The available data (from EORTC-ISG-AGITG 62005 trial and meta-analysis with S0033) have shown that the response of patients with exon 9 *KIT* mutations depends on the dose of the drug and that these patients under higher does (800 mg daily) of imatinib demonstrate significant improvement of PFS as compared to a standard dose of 400 mg daily (without impact on OS) \[[@CR17], [@CR36]\]. Furthermore, although the presence of *PDGFRA* D842V mutation is related to more indolent disease in primary resectable GIST \[[@CR37]\], it is poor prognostic factor in advanced disease, as this mutation is insensitive to commonly used tyrosine kinase inhibitors (including imatinib and sunitinib) \[[@CR33], [@CR38]\] and is responsible for primary resistance to imatinib.

Surgery of residual disease in situation of absence of disease progression was found as the most independent prognostic factor for better outcomes in advanced GIST. Some studies have already reported favorable outcomes of surgery in responding patients \[[@CR10], [@CR39]--[@CR42]\]. The present series demonstrate clear improvement in the long-term term survival in the group of patients operated after response to imatinib therapy (median PFS and OS were not reached). Although we cannot exclude selection bias as the role of surgery in metastatic GIST has never been confirmed in prospective study (as the initiated studies failed because of slow recruitment) \[[@CR43]\], we still believe in real impact of this strategy on natural course of the disease. It can theoretically prolong durable remission, because the excision of the tumor is performed before the development of imatinib resistance, and thus, the risk of resistant clone selection is reduced. We have rather liberally used surgical removal of residual disease after individual decision made on multidisciplinary tumor board, as more than 20 % patients responding to systemic therapy underwent surgery following imatinib therapy, what might reduce the impact of initial tumor size at advanced setting.

Although imatinib is the most important therapy in GIST, predominantly influencing survival in advanced disease, the difference between median PFS and OS on initial therapy with imatinib in our study is more than 2.5 years. There are several reasons for these results, suggesting relative efficacy of salvage therapy after imatinib failure. Multidisciplinary approach after progression on initial dose of imatinib includes increase of the dose of imatinib to 800 mg daily \[[@CR44]\], surgical resection, or ablation of focally progressive disease \[[@CR10], [@CR39], [@CR42]\], using therapy with alternative receptor tyrosine kinase inhibitors (as second-line registered multi-targeted tyrosine inhibitor sunitinib, or further line therapy with sorafenib or regorafenib, which recently has been approved in USA) \[[@CR7], [@CR45]\]. We have recently analyzed the results of sunitinib therapy in series of 137 patients after failure of imatinib therapy and demonstrated survival exceeding 1.5 years from start of sunitinib \[[@CR36]\], as well as we have also proven that contrary to imatinib, tumors initially (pre-imatinib treatment) bearing *KIT* exon 9 mutation or with wild-type genotype have a higher chance to respond to sunitinib. We also actively used therapy with alternative tyrosine kinase inhibitors after progression on imatinib and sunitinib (not only best supportive care), which also may be related to better OS observed in our study \[[@CR46]\] and lack of differences between different periods of treatment.

To summarize, the current median survival in advanced GIST reaches 6 years. The long-term survivors (with OS exceeding 5 years) were characterized by smaller maximal tumors at start of imatinib therapy, better laboratory tests results, better performance status, and more commonly use of surgical removal of residual disease. The latter might reduce the impact of tumor size and equalize the long-term results of therapy during last decade from the introduction of imatinib. In addition, after introduction of subsequent lines of therapy, the effect of primary mutational status (with exception of *PDGFRA*-D842V) on long-term OS is less visible.
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